Non-Schitzo Covid Vaccine thread
No.13960249 ViewReplyOriginalReport
Quoted By: >>13960269 >>13960386 >>13960602 >>13960677 >>13960837
I want to see the actual data and evidence concerning Covid, the vaccine, and adverse events. I just briefly crunched the numbers and I think it's pretty clear the elevated risk for an adverse event in the form of myocarditis/pericarditis in young men is greater than the risk of severe disease by the virus.
Myocarditis/pericarditis adverse events (MPAE) transpired immediately (median of 3 days) after the 2nd vaccination. 1522 reported cases in VAERS as of 02SEP2021, these are confirmed by objective lab results. 76.8% of patients received the Pfizer-BioNTech vaccine and 23.2% received the Moderna vaccine. 88.5% of MPAE's developed symptoms after the second dose
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641964/
On the <30 demographic that has received both doses of a vaccine, the CDC says:
>By May 22, 2021 coverage for 18–29 years was 38.3%
https://www.cdc.gov/mmwr/volumes/70/wr/mm7025e1.htm
This is 4 months before the VAERS data above was collected, so the percentage of the population vaccinated may have been higher at the limit of the VAERS data. The rate of vaccination has a sex difference which favors women. I don't know how large the gap is but we'll use 30% as the number for male vaccinated within this demo as a guess.
https://pioneerinstitute.org/covid/why-does-a-gender-gap-persist-in-vaccination-rates/
There's ~53.3 million people in the 18-29 demo. We can cut it in half to isolate males as they're the ones who are at risk, ~26.7 mil.
(26.7 mil)(.3)= 8,010,000
1255/8,010,000 = 0.00019001248
0.00019001248*10^5 = 19 per 100k
Myocarditis/pericarditis adverse events (MPAE) transpired immediately (median of 3 days) after the 2nd vaccination. 1522 reported cases in VAERS as of 02SEP2021, these are confirmed by objective lab results. 76.8% of patients received the Pfizer-BioNTech vaccine and 23.2% received the Moderna vaccine. 88.5% of MPAE's developed symptoms after the second dose
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641964/
On the <30 demographic that has received both doses of a vaccine, the CDC says:
>By May 22, 2021 coverage for 18–29 years was 38.3%
https://www.cdc.gov/mmwr/volumes/70/wr/mm7025e1.htm
This is 4 months before the VAERS data above was collected, so the percentage of the population vaccinated may have been higher at the limit of the VAERS data. The rate of vaccination has a sex difference which favors women. I don't know how large the gap is but we'll use 30% as the number for male vaccinated within this demo as a guess.
https://pioneerinstitute.org/covid/why-does-a-gender-gap-persist-in-vaccination-rates/
There's ~53.3 million people in the 18-29 demo. We can cut it in half to isolate males as they're the ones who are at risk, ~26.7 mil.
(26.7 mil)(.3)= 8,010,000
1255/8,010,000 = 0.00019001248
0.00019001248*10^5 = 19 per 100k